Imperial’s coronavirus vaccine could be available in early 2021Lockdown is easing across the UK but life is far from the pre-coronavirus “normal” in the absence of a Share XImperial’s coronavirus vaccine could be available in early 2021https://pharmaphorum.com/news/imperials-coronavirus-vaccine-could-be-available-in-early-2021/
Gilead finds survival boost with remdesivir with unorthodox analysisGilead says an analysis of clinical trial and retrospective real-world data suggest remdesivir can improve survival in severe Share XGilead finds survival boost with remdesivir with unorthodox analysishttps://pharmaphorum.com/news/gilead-finds-survival-boost-with-remdesivir-with-unorthodox-analysis/
Pharma companies create $1bn fund to save antibiotic researchMore than 20 pharma companies including GlaxoSmithKline, Novartis and Pfizer have joined forces to create a $1 billion Share XPharma companies create $1bn fund to save antibiotic researchhttps://pharmaphorum.com/news/pharma-companies-create-1bn-fund-to-save-antibiotic-research/
Kymera Therapeutics begins potential $2bn R&D deal with SanofiUS biotech Kymera Therapeutics has begun a strategic collaboration with Sanofi to develop and market several drugs tackling immune-inflammatory disease, which Share XKymera Therapeutics begins potential $2bn R&D deal with Sanofihttps://pharmaphorum.com/news/kymera-therapeutics-begins-potential-2bn-rd-deal-with-sanofi/
Gilead starts trials of inhaled remdesivir for earlier-stage COVID-19The first healthy volunteers have started to receive doses of Gilead’s inhaled formulation of remdesivir, which it hopes Share XGilead starts trials of inhaled remdesivir for earlier-stage COVID-19https://pharmaphorum.com/news/gilead-starts-trials-of-inhaled-remdesivir-for-earlier-stage-covid-19/
Regeneron begins late-stage trial testing COVID-19 antibody cocktailRegeneron has begun a late-stage clinical trial testing its double “antibody cocktail” as a preventive treatment for COVID-19. Share XRegeneron begins late-stage trial testing COVID-19 antibody cocktailhttps://pharmaphorum.com/news/regeneron-begins-late-stage-trial-testing-covid-19-antibody-cocktail/
UK trial begins testing second-wave COVID-19 drug from US biotech RidgebackThe AGILE programme, which is researching a second wave of COVID-19 therapies in the UK, has begun testing its first potential Share XUK trial begins testing second-wave COVID-19 drug from US biotech Ridgebackhttps://pharmaphorum.com/news/uk-trial-begins-testing-second-wave-covid-19-drug-from-us-biotech-ridgeback/
CureVac claims €75m in EU funding for mRNA COVID-19 vaccineGerman vaccine firm CureVac has been awarded a €75 million loan from the European Investment Bank to boost Share XCureVac claims €75m in EU funding for mRNA COVID-19 vaccinehttps://pharmaphorum.com/news/curevac-claims-e75m-in-eu-funding-for-mrna-covid-19-vaccine/
Idorsia on course to take on Eisai and Merck & Co after latest insomnia phase 3 trial winSwitzerland’s Idorsia says it is on course to file a potential next-generation insomnia drug around the end of this year after a Share XIdorsia on course to take on Eisai and Merck & Co after latest insomnia phase 3 trial winhttps://pharmaphorum.com/news/idorsia-on-course-to-take-on-eisai-and-merck-co-after-latest-insomnia-phase-3-trial-win/
GSK and Sanofi close in on £500m COVID-19 vaccine deal with UK – reportGlaxoSmithKline and Sanofi are close to agreeing a £500m deal to supply the UK government with 60 million Share XGSK and Sanofi close in on £500m COVID-19 vaccine deal with UK – reporthttps://pharmaphorum.com/news/gsk-and-sanofi-close-in-on-500m-covid-19-vaccine-deal-with-uk-report/
IL-6 hypothesis looking shaky as Kevzara fails COVID-19 trialHopes that already-approved drugs targeting IL-6 could be repurposed to treat COVID-19 have been undermined by disappointing results Share XIL-6 hypothesis looking shaky as Kevzara fails COVID-19 trialhttps://pharmaphorum.com/news/il-6-hypothesis-looking-shaky-as-kevzara-fails-covid-19-trial/
Payments from UK pharma to healthcare professionals increased in 2019The UK’s pharmaceutical industry has published headline figures from its Disclosure UK scheme, showing payments from pharma to Share XPayments from UK pharma to healthcare professionals increased in 2019https://pharmaphorum.com/news/payments-from-uk-pharma-to-healthcare-professionals-increased-in-2019/
Pfizer/BioNTech’s COVID-19 vaccine neutralises virus in early studyPfizer and BioNTech have announced early results from their ongoing phase 1 /2 study of a potential COVID-19 coronavirus vaccine, showing Share XPfizer/BioNTech’s COVID-19 vaccine neutralises virus in early studyhttps://pharmaphorum.com/news/pfizer-biontech-eye-phase/
Bharat Biotech begins trial of COVID-19 vaccine in India as cases mountBharat Biotech is to begin trials of a coronavirus vaccine in India as the country faces a rapidly growing Share XBharat Biotech begins trial of COVID-19 vaccine in India as cases mounthttps://pharmaphorum.com/news/bharat-biotech-begins-trial-of-covid-19-vaccine-in-india-as-cases-mount/
Intercept CEO lays into FDA after NASH drug rejectionIntercept Pharmaceuticals has accused the FDA of moving the goalposts during its review of a potential blockbuster drug for the fatty Share XIntercept CEO lays into FDA after NASH drug rejectionhttps://pharmaphorum.com/news/intercept-ceo-lays-into-fda-after-nash-drug-rejection/
Trial starts with Imperial College London coronavirus vaccineThe first healthy volunteer has been dosed with Imperial College London’s coronavirus vaccine, the second UK-developed candidate to Share XTrial starts with Imperial College London coronavirus vaccinehttps://pharmaphorum.com/news/trial-starts-with-imperial-college-london-coronavirus-vaccine/
Medical charities “slipping through cracks” of UK pandemic supportCharities have already been hit hard by the coronavirus pandemic and lockdown, and Cancer Research UK says it Share XMedical charities “slipping through cracks” of UK pandemic supporthttps://pharmaphorum.com/news/medical-charities-slipping-through-cracks-of-uk-pandemic-support/
Sanofi and Translate Bio expand mRNA vaccine agreementSanofi’s Pasteur vaccines unit and Translate Bio have expanded a collaboration to develop mRNA-based vaccines across all infectious Share XSanofi and Translate Bio expand mRNA vaccine agreementhttps://pharmaphorum.com/news/sanofi-and-translate-bio-expand-mrna-vaccine-agreement/
